Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Approach for Basal Insulin Titration in T2D
NCT04864977Phase 4Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2021
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Planned start Aug 2021; status: withdrawn.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04864977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04864977.